Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Beuzeboc

Showing results (51-60 of 128) with videos related to

Pageof 13
Sort By:
Virchows Archiv : an International Journal of Pathology|March 19, 2004
Confrontation of immunohistochemistry and fluorescent in situ hybridization for the assessment of HER-2/ neu (c-erbb-2) status in urothelial carcinomaGonzague de Pinieux, Delphine Colin, Anne Vincent-Salomon, et al.
European Journal of Cancer (Oxford, England : 1990)|November 23, 2021
Letter comments on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single-centre prospective study: Interaction between lymphopenia and anti-SARS-CoV-2 antibodies after two injections of the Pfizer-BioNTech vaccine in patients with cancers treated by chemotherapy or immunotherapySakina Sekkate, Henri-Corto Stoeklé, May Mabro, et al.
Bulletin Du Cancer|November 20, 2021
[Homologous recombination deficiency and PARP inhibitors in therapeutics]Hélène Salaün, Mathilde Saint-Ghislain, Audrey Bellesoeur, et al.
European Urology|December 2, 2008
Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trialNicholas D James, Armelle Caty, Michael Borre, et al.
Anti-Cancer Drugs|August 19, 2006
Gemcitabine and cisplatin after radical cystectomy for bladder cancer in an adjuvant setting: feasibility study from the Genito-Urinary Group of the French Federation of Cancer CentersAude Fléchon, Karim Fizazi, Sophie Gourgou-Bourgade, et al.
BJU International|January 21, 2015
Intermediate analysis of a phase II trial assessing gemcitabine and cisplatin in locoregional or metastatic penile squamous cell carcinomaNadine Houédé, Laura Dupuy, Aude Fléchon, et al.
Bulletin Du Cancer|November 23, 2011
[Renal insufficiency and breast cancer]Philippe Beuzeboc, Christophe Le Tourneau, Joseph Gligorov, et al.
BMC Medical Ethics|August 28, 2022
From a voluntary vaccination policy to mandatory vaccination against COVID-19 in cancer patients: an empirical and interdisciplinary study in bioethicsHenri-Corto Stoeklé, Sakina Sekkate, Elisabeth Angellier, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|February 8, 2006
[Follow-up of prostate cancer. Guidelines of the Comité de Cancérologie de l'Association Française d'Urologie]Pierre Richaud, Jean-Luc Moreau, Philippe Beuzeboc, et al.
Urology|August 15, 2006
Management of a malignant urinary fistula by ureteral embolization with coilsDelphine Amsellem-Ouazana, François Cornud, Sophie Conquy, et al.
Pageof 13

Showing results (51-60 of 128) with videos related to

Sort By:
Pageof 13
Virchows Archiv : an International Journal of Pathology|March 19, 2004
Confrontation of immunohistochemistry and fluorescent in situ hybridization for the assessment of HER-2/ neu (c-erbb-2) status in urothelial carcinomaGonzague de Pinieux, Delphine Colin, Anne Vincent-Salomon, et al.
European Journal of Cancer (Oxford, England : 1990)|November 23, 2021
Letter comments on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single-centre prospective study: Interaction between lymphopenia and anti-SARS-CoV-2 antibodies after two injections of the Pfizer-BioNTech vaccine in patients with cancers treated by chemotherapy or immunotherapySakina Sekkate, Henri-Corto Stoeklé, May Mabro, et al.
Bulletin Du Cancer|November 20, 2021
[Homologous recombination deficiency and PARP inhibitors in therapeutics]Hélène Salaün, Mathilde Saint-Ghislain, Audrey Bellesoeur, et al.
European Urology|December 2, 2008
Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trialNicholas D James, Armelle Caty, Michael Borre, et al.
Anti-Cancer Drugs|August 19, 2006
Gemcitabine and cisplatin after radical cystectomy for bladder cancer in an adjuvant setting: feasibility study from the Genito-Urinary Group of the French Federation of Cancer CentersAude Fléchon, Karim Fizazi, Sophie Gourgou-Bourgade, et al.
BJU International|January 21, 2015
Intermediate analysis of a phase II trial assessing gemcitabine and cisplatin in locoregional or metastatic penile squamous cell carcinomaNadine Houédé, Laura Dupuy, Aude Fléchon, et al.
Bulletin Du Cancer|November 23, 2011
[Renal insufficiency and breast cancer]Philippe Beuzeboc, Christophe Le Tourneau, Joseph Gligorov, et al.
BMC Medical Ethics|August 28, 2022
From a voluntary vaccination policy to mandatory vaccination against COVID-19 in cancer patients: an empirical and interdisciplinary study in bioethicsHenri-Corto Stoeklé, Sakina Sekkate, Elisabeth Angellier, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|February 8, 2006
[Follow-up of prostate cancer. Guidelines of the Comité de Cancérologie de l'Association Française d'Urologie]Pierre Richaud, Jean-Luc Moreau, Philippe Beuzeboc, et al.
Urology|August 15, 2006
Management of a malignant urinary fistula by ureteral embolization with coilsDelphine Amsellem-Ouazana, François Cornud, Sophie Conquy, et al.
Pageof 13